Dr. Reddys Laboratories is currently trading at Rs. 2504.00, up by 53.65 points or 2.19% from its previous closing of Rs. 2450.35 on the BSE.
The scrip opened at Rs. 2491.00 and has touched a high and low of Rs. 2526.45 and Rs. 2447.15 respectively. So far 4276 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2687.45 on 28-Sep-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.
Last one week high and low of the scrip stood at Rs. 2600.05 and Rs. 2332.10 respectively. The current market cap of the company is Rs. 40687.05 crore.
The promoters holding in the company stood at 26.79%, while Institutions and Non-Institutions held 44.27% and 14.60% respectively.
Dr. Reddy’s Laboratories has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla in Hyderabad, to Therapiva an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and its employees. Therapiva is a joint venture between Omnicare Drugs India (100% subsidiary of Neopharma LLC, Abu Dhabi) and Laxai Life Sciences.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |